

# Inducible nitric oxide synthase gene deficiency counteracts multiple manifestations of peripheral neuropathy in a streptozotocin-induced mouse model of diabetes

I. Vareniuk · I. A. Pavlov · I. G. Obrosova

Received: 3 June 2008 / Accepted: 22 July 2008 / Published online: 19 September 2008  
© Springer-Verlag 2008

## Abstract

**Aims/hypothesis** Evidence for the importance of peroxynitrite, a product of superoxide anion radical reaction with nitric oxide, in peripheral diabetic neuropathy is emerging. The role of specific nitric oxide synthase isoforms in diabetes-associated nitrosative stress and nerve fibre dysfunction and degeneration remains unknown. This study evaluated the contribution of inducible nitric oxide synthase (iNOS) to peroxynitrite injury to peripheral nerve and dorsal root ganglia and development of peripheral diabetic neuropathy. **Methods** Control mice and mice with *iNos* (also known as *Nos2*) gene deficiency (*iNos*<sup>-/-</sup>) were made diabetic with streptozotocin, and maintained for 6 weeks. Peroxynitrite injury was assessed by nitrotyrosine and poly(ADP-ribose) accumulation (immunohistochemistry). Thermal allgesia was evaluated by paw withdrawal, tail-flick and hot plate tests, mechanical allgesia by the Randall–Selitto test, and tactile allodynia by a von Frey filament test. **Results** Diabetic wild-type mice displayed peroxynitrite injury in peripheral nerve and dorsal root ganglion neurons. They also developed motor and sensory nerve conduction velocity deficits, thermal and mechanical hypoalgesia, tactile allodynia and ~36% loss of intraepidermal nerve fibres. Diabetic *iNos*<sup>-/-</sup> mice did not display nitrotyrosine and poly(ADP-ribose) accumulation in peripheral nerve, but were not protected from nitrosative stress in dorsal root ganglia. Despite this latter circumstance, diabetic *iNos*<sup>-/-</sup> mice preserved normal nerve conduction velocities. Small-

fibre sensory neuropathy was also less severe in diabetic *iNos*<sup>-/-</sup> than in wild-type mice.

**Conclusions/interpretation** iNOS plays a key role in peroxynitrite injury to peripheral nerve, and functional and structural changes of diabetic neuropathy. Nitrosative stress in axons and Schwann cells, rather than dorsal root ganglion neurons, underlies peripheral nerve dysfunction and degeneration.

**Keywords** iNOS · Nerve conduction · Nitrosative stress · Peripheral diabetic neuropathy · Tactile allodynia · Thermal allgesia

## Abbreviations

DAB	3,3'-diaminobenzidine
DRG	dorsal root ganglion
INFD	intraepidermal nerve fibre density
iNOS	inducible nitric oxide synthase
MNCV	motor nerve conduction velocity
NT	nitrotyrosine
PAR	poly(ADP-ribose)
PARP	poly(ADP-ribose) polymerase
PDN	peripheral diabetic neuropathy
PGP 9.5	protein gene product 9.5
SNCV	sensory nerve conduction velocity
STZ	streptozotocin
TBS	TRIS-buffered saline

## Introduction

Diabetic distal symmetric sensorimotor polyneuropathy affects ~50% of patients with diabetes mellitus, and is a leading cause of foot amputation [1]. Evidence for the important role of the highly reactive oxidant peroxynitrite

I. Vareniuk · I. A. Pavlov · I. G. Obrosova (✉)  
Pennington Biomedical Research Center,  
Louisiana State University System,  
6400 Perkins Road,  
Baton Rouge, LA 70808, USA  
e-mail: obrosoig@pbrc.edu

[2, 3] in peripheral diabetic neuropathy (PDN) is emerging from both experimental [4–7] and clinical [8–10] studies. Accumulation of nitrotyrosine (NT), a footprint of peroxynitrite injury, has been found in peripheral nerve, vasa nervorum, spinal cord and dorsal root ganglion (DRG) neurons in animal models of both type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes [3–7, 11–13] and high glucose-exposed cultured human Schwann cells [14]. Recent experimental studies with peroxynitrite decomposition catalysts revealed an important contribution of peroxynitrite-induced injury (so called nitrosative stress) to diabetes-induced motor and sensory nerve conduction deficits, small sensory nerve fibre dysfunction and degeneration, and autonomic neuropathy [3–7, 15]. Clinical studies revealed increased plasma NT levels and their correlation with endothelial dysfunction and redistribution of sudomotor responses, an early sign of sympathetic nerve dysfunction, in type 1 diabetic patients [8–10]. Furthermore, plasma peroxynitrite generation assessed by the pholasin chemiluminescence test correlated with the diabetic neuropathy impairment score of the lower limbs [10].

Peroxyntirite is a product of superoxide anion radical reaction with nitric oxide. The latter can be produced by several nitric oxide synthase isoforms, i.e. endothelial nitric oxide synthase, inducible nitric oxide synthase (iNOS), and neuronal nitric oxide synthase. Whereas all three isoforms have been localised in the peripheral nervous system [14, 16, 17], their individual contributions to peroxynitrite-induced injury in tissue targets for PDN and development of nerve fibre dysfunction and degeneration remain unknown. Here, we provide the first evidence of the key role of iNOS in diabetes-induced nitrosative stress in the peripheral nerve, nerve conduction deficit, and small-fibre sensory neuropathy.

## Methods

### Reagents

Unless otherwise stated, all chemicals were of reagent-grade quality, and were purchased from Sigma Chemical Company, St Louis, MO, USA. Rabbit polyclonal anti-NT antibody was purchased from Upstate (Lake Placid, NY, USA) and mouse monoclonal anti-poly(ADP-ribose) (PAR) from Trevigen (Gaithersburg, MD, USA). Secondary Alexa Fluor 488 goat anti-rabbit and Alexa Fluor 488 goat anti-mouse antibodies as well as Prolong Gold Antifade Reagent were purchased from Invitrogen (Eugene, OR, USA). Avidin/Biotin Blocking Kit, M.O.M. Basic Kit, VECTAS-TAIN Elite ABC Kit (Standard\*), DAB Substrate Kit, and 3,3'-diaminobenzidine (DAB) were obtained from Vector

Laboratories (Burlingame, CA, USA). Rabbit polyclonal anti-protein gene product 9.5 (PGP 9.5) (ubiquitin C-terminal hydrolase) antibody was purchased from Chemicon International (Temecula, CA, USA). Other reagents for immunohistochemistry were purchased from Dako Laboratories (Santa Barbara, CA, USA).

### Animals and limitations of the model of mice with *iNos* gene deficiency

The experiments were performed in accordance with regulations specified by the National Institutes of Health 'Principles of Laboratory Animal Care, 1985 Revised Version' and the Pennington Biomedical Research Center Protocol for Animal Studies. Several breeding pairs of B6.129P2-*Nos2*<sup>tm1Lau/J</sup> (*iNos*<sup>-/-</sup>) mice, C57Bl6/J background, were obtained from Jackson Laboratories (Bar Harbor, ME, USA; stock number 002609). The use of *iNos*<sup>-/-</sup> mice for neurological studies is associated with some limitations because *iNos* gene (also known as *Nos2*) deficiency is known to result in impaired spinal cord regeneration, abnormal oligodendrocyte morphology and increased demyelination after neurotoxicant treatment (<http://jaxmice.jax.org/strain/002609.html>). Nevertheless, *iNos*<sup>-/-</sup> mice have normal motor and sensory nerve conduction velocities (MNCV and SNCV), normal thermal and mechanical allgesia and tactile response thresholds, and, for this reason, have been considered suitable for assessment of the role of iNOS in PDN.

For the main experiment, a colony of *iNos*<sup>-/-</sup> mice was established at Pennington Biomedical Research Center. Mature male C57Bl6/J mice were purchased from Jackson Laboratories and served as controls. All the mice were fed standard mouse chow (PMI Nutrition International, Brentwood, MO, USA) and had access to water ad libitum. Diabetes was induced by a single injection of streptozotocin (STZ), 100 mg kg<sup>-1</sup> day<sup>-1</sup>, i.p., to non-fasted animals. Blood samples for glucose measurements were taken from the tail vein 3 days after STZ injection and the day before the animals were killed. The mice with blood glucose  $\geq 13.8$  mmol/l were considered diabetic. The injected mice that had blood glucose concentrations in the non-diabetic range were given low-dose STZ injections (40 mg kg<sup>-1</sup> day<sup>-1</sup>, i.p.) until they developed hyperglycaemia (typically, one to three additional injections). At the end of the study (duration of diabetes of 6 weeks), the physiological and behavioural tests were performed in the following order: tactile responses to flexible von Frey filaments (first day), tail-pressure Randall–Sellito test (second day), thermal allgesia by tail-flick test (third day), thermal allgesia by paw withdrawal test (fourth day), thermal allgesia by hot plate test (fifth day), SNCV and MNCV (sixth day). Measurements of

MNCV and SNCV were performed in mice anaesthetised with a mixture of ketamine and xylazine (45 mg/kg body weight and 15 mg/kg body weight, respectively, i.p.).

#### Anaesthesia, killing and tissue sampling

The animals were sedated by CO<sub>2</sub>, and immediately killed by cervical dislocation. Sciatic nerves, DRG and foot pads were fixed in 10% neutral buffered formalin solution containing 4% (wt/vol.) formaldehyde (Sigma-Aldrich, Saint Louis, MO, USA) for assessment of NT and PAR by immunofluorescence histochemistry and intraepidermal nerve fibre density by conventional immunohistochemistry. PAR abundance is a measure of PAR polymerase (PARP) activity [18, 19].

#### Specific methods

*Physiological tests* Sciatic MNCV and hindlimb digital SNCV were measured as we have described elsewhere [3, 20]. A TCAT-2 Temperature Controller with a RET-3 Temperature probe and an HL-1 Heat Lamp (Physitemp Instruments, Clifton, NJ, USA) was used to maintain body and hindlimb temperature at 37°C.

*Behavioural tests* Tactile responses were evaluated by quantifying the withdrawal threshold of the hind paw in response to stimulation with flexible von Frey filaments as we have described [13]. Tail pressure thresholds were registered with a Paw/Tail Pressure Analgesia meter for the Randall–Selitto test (37215; Analgesy-Meter, UGO-Basile, Comerio VA, Italy). Pressure increasing at a linear rate of 10 g with the cut-off of 250 g to avoid tissue injury, was applied to the base of the tail. The applied tail pressure that evoked biting or licking behaviour was registered by an analgesia meter and expressed in grams. Three tests separated by at least 15 min were performed for each animal, and the mean value of these tests was calculated.

For thermal algnesia, the paw withdrawal latency in response to the radiant heat (15% intensity, which produced a heating rate of ~1.3°C/s, cut-off time 30 s) was determined as we have described [5–7, 12, 13] using an IITC model 336 TG combination tail-flick and paw algnesia meter (IITC Life Science, Woodland Hills, CA, USA) with a floor temperature ~32–33°C (manufacturer's set up). For assessment of tail-flick response latencies, the device was set at 40% heating intensity (heating rate ~2.5°C/s) with a cut-off at 10 s. In the hot plate test (IITC Model 39 Hot Plate Analgesia Meter; IITC Life Science) the unit had a plate preset temperature of 55°C. In all three tests, at least three readings per animal were taken at 15 min interval, and the average was calculated.

*Immunohistochemical studies* All sections were processed by a single investigator and evaluated blindly. Low-power observations of skin sections stained for PGP 9.5 were made using a Zeiss Axioskop microscope (Carl Zeiss Imaging, Thornwood, NY, USA). Colour images were captured with a Zeiss Axiocam HRc CCD camera at 1,300×1,030 resolution (Carl Zeiss Imaging). Low-power images were generated with a ×40 acroplan objective using the automatic capturing feature of the Zeiss Axiovision software (Ver. 3.1.2.1). Low-power observations of sciatic nerve and DRG sections stained for NT and PAR were made using a Zeiss Axioplan 2 imaging microscope. Colour images were captured with a Photometric CoolSNAP<sub>HQ</sub> CCD camera (Photometrics Sales, Tucson, AZ, USA) at 1,392×1,040 resolution. Low-power images were generated with a ×40 acroplan objective using RS Image 1.9.2 software (Photometrics Sales).

NT immunoreactivities in the sciatic nerve and DRG were assessed by immunofluorescence histochemistry. In brief, sections were deparaffinised in xylene, rehydrated in decreasing concentrations of ethanol and washed in water. For immunofluorescence histochemistry, rabbit polyclonal anti-NT antibody was used in a working dilution of 1:400. Primary antibody was omitted in negative controls. Secondary Alexa Fluor 488 goat anti-rabbit antibody was applied in a working dilution of 1:200. Sections were mounted in Prolong Gold Antifade Reagent. The intensity of fluorescence was quantified using ImageJ 1.32 software (National Institutes of Health, Bethesda, MD, USA) and expressed as mean±SEM for each experimental group.

PAR immunoreactivity was assessed as described [20] with minor modifications. In brief, sections of peripheral nerve and DRG were deparaffinised in xylene, rehydrated in decreasing concentrations of ethanol and washed in water. Non-specific binding was blocked with the mouse Ig blocking reagent supplied with the Vector M.O.M. Basic Immunodetection Kit. Then mouse monoclonal anti-PAR antibody was diluted 1:100 in 1% BSA in TRIS-buffered saline (TBS), and applied overnight at 4°C in the humidity chamber. Primary antibody was omitted in negative controls. Secondary Alexa Fluor 488 goat anti-mouse antibody was diluted 1:200 in TBS and applied for 2 h at room temperature. Sections were mounted in Prolong Gold Antifade Reagent. At least ten fields of each section were examined to select one representative image. Representative images were microphotographed. The number of nuclei with identifiable PAR fluorescence was calculated for each microphotograph and expressed as mean±SEM for each experimental group. To evaluate neuronal PAR accumulation, a percentage of DRG neurons with weak, moderate and intense PAR immunofluorescence was calculated for each experimental group.

Intraepidermal nerve fibre density (INFD) was assessed as described [5, 6, 12, 13]. Three randomly chosen 5  $\mu$ m sections from foodpad skin of each mouse were deparaffinised in xylene, hydrated in decreasing concentrations of ethanol, and washed in water. Non-specific binding was blocked by 10% goat serum containing 1% BSA in TBS (DAKO, Carpinteria, CA, USA) for 2 h, and the Avidin/Biotin Blocking kit, according to the manufacturer's instructions. Then, rabbit polyclonal anti-PGP 9.5 antibody was applied in a 1:2,000 dilution. Secondary biotinylated goat anti-rabbit IgG (H+L) antibody was applied in a 1:400 dilution, and the staining performed with the VECTAS-TAIN Elite ABC Kit (Standard\*). For visualisation of specific binding sites, the DAB Substrate Kit containing DAB was used. Sections were counterstained with Gill's haematoxylin, dehydrated and mounted in Micromount mounting medium (Surgipath Medical, Richmond, IL, USA). Intraepidermal nerve fibre profiles were counted blindly by three independent investigators, under an Olympus BX-41 microscope (Leeds Precision Instruments, Minneapolis, MN, USA), and the average values were used. Microphotographs of stained sections were taken on an Axioscop 2 microscope (Zeiss) at  $\times 4$  magnification, and the length of epidermis was assessed with the ImagePro 3.0 program (Media Cybernetics, Bethesda, MD, USA). An average of  $2.8 \pm 0.3$  mm of the sample length was investigated to calculate a number of nerve fibre profiles per mm of epidermis.

#### Statistical analysis

Results are expressed as means  $\pm$  SEM. Data were subjected to equality of variance *F* test, and then to  $\log_{10}$  transformation, if necessary, before one-way ANOVA. Where overall significance ( $p < 0.05$ ) was attained, individual between-group comparisons were made using the Student–Newman–Keuls multiple-range test. Significance was defined at  $p \leq 0.05$ . When between-group variance differences could not be normalised by log transformation (datasets for body weights and plasma glucose), the data

were analysed by the non-parametric Kruskal–Wallis one-way ANOVA, followed by the Bonferroni–Dunn test for multiple comparisons.

#### Results

Weight gain during the 6 week study was comparable in non-diabetic wild-type (17%) and non-diabetic *iNos*<sup>-/-</sup> (20%) mice (Table 1). Whereas diabetic wild-type mice lost 14% of their initial body weight, diabetic *iNos*<sup>-/-</sup> mice did not display any weight loss, and moreover, gained 5% of weight. Initial (after STZ injection) blood glucose concentrations were 72% and 79% higher in diabetic wild-type and diabetic *iNos*<sup>-/-</sup> mice compared with the corresponding controls. Hyperglycaemia progressed with the prolongation of diabetes, and the difference between final blood glucose concentrations in both groups and corresponding controls exceeded threefold. Final blood glucose concentrations were similar in diabetic wild-type and diabetic *iNos*<sup>-/-</sup> mice.

Sciatic MNCV and hindlimb SNCV were 20 and 14% lower in diabetic wild-type mice compared with non-diabetic controls ( $p < 0.01$  for both comparisons, Fig. 1a, b). In contrast, diabetic *iNos*<sup>-/-</sup> mice preserved normal MNCV and SNCV.


The latency of hind-paw withdrawal in response to radiant heat was increased by 103% in diabetic wild-type mice compared with the control group ( $p < 0.01$ ), consistent with clearly manifest thermal hypoalgesia (Fig. 2a). This is in agreement with the results of tail-flick and hot plate tests, which also revealed increased thermal response latencies in the diabetic wild-type mice (Fig. 2b,c). In contrast, only very minor hypoalgesia (a 10% increase in the response latency) was registered with the hind-paw withdrawal test in diabetic *iNos*<sup>-/-</sup> mice. Note, however, that tail-flick response latencies were similarly increased in diabetic wild-type (21%) and diabetic *iNos*<sup>-/-</sup> (17%) mice compared with the corresponding non-diabetic controls. The hot plate test results were in the normal range in diabetic *iNos*<sup>-/-</sup> mice.

**Table 1** Initial and final body weights and blood glucose concentrations in experimental groups

Group	Body weight (g)		Blood glucose (mmol/l)	
	Initial	Final	Initial	Final
Non-diabetic wild-type	28.6 $\pm$ 0.9	31.4 $\pm$ 0.7	8.6 $\pm$ 0.4	9.0 $\pm$ 0.4
Non-diabetic <i>iNos</i> <sup>-/-</sup>	26.2 $\pm$ 0.7	32.1 $\pm$ 1.0	8.2 $\pm$ 0.3	9.1 $\pm$ 0.4
Diabetic wild-type	30.6 $\pm$ 0.8	26.2 $\pm$ 0.8**	15.3 $\pm$ 0.9**	29.3 $\pm$ 1.15**
Diabetic <i>iNos</i> <sup>-/-</sup>	25.6 $\pm$ 0.6	26.8 $\pm$ 0.4**	19.1 $\pm$ 1.1**	27.9 $\pm$ 1.5**

Data are means  $\pm$  SEM,  $n = 8$ –11 per group

Significantly different from the corresponding non-diabetic groups (\*\* $p < 0.01$ )




**Fig. 1** Sciatic MNCV (a) and hindlimb digital sensory nerve conduction velocities (b) in control (C) and diabetic (D) wild-type and *iNos*<sup>-/-</sup> mice. Means±SEM, *n*=6–8 per group. \*\**p*<0.01 vs corresponding non-diabetic groups; ††*p*<0.01 vs diabetic wild-type mice

Diabetic wild-type and *iNos*<sup>-/-</sup> mice displayed moderate mechanical hypoalgesia detected with the tail pressure Randall–Sellito test (Fig. 3a). The tail pressure threshold was increased by 19% in diabetic wild-type mice and by 13% in diabetic *iNos*<sup>-/-</sup> mice compared with the corresponding non-diabetic groups (*p*<0.05 and *p*>0.05, respectively). The severity of tactile allodynia was lower in diabetic wild-type compared with diabetic *iNos*<sup>-/-</sup> mice (Fig. 3b). Tactile response thresholds were reduced by 70% in diabetic wild-type mice and by 40% in diabetic *iNos*<sup>-/-</sup> mice compared with the corresponding untreated groups (*p*<0.01 for both comparisons).

INFD was reduced by 36% in diabetic wild-type mice and by 14% in diabetic *iNos*<sup>-/-</sup> mice compared with the corresponding controls (*p*<0.05 and *p*>0.05, respectively, Fig. 4a,b). Note, however, that *iNos* gene deficiency was associated with a ~10% decrease in INFD in non-diabetic mice.

NT immunofluorescence was increased by 69% in the sciatic nerves of diabetic wild-type mice compared with non-diabetic controls (*p*<0.01, Fig. 5a,b). In contrast, no diabetes-induced NT accumulation was detected in the




**Fig. 3** Mechanical withdrawal thresholds in tail-pressure Randall–Sellito tests (a) and tactile response thresholds in response to stimulation with flexible von Frey filaments (b) in control (C) and diabetic (D) wild-type and *iNos*<sup>-/-</sup> mice. Means±SEM, *n*=6–11 per group. \*\**p*<0.01 vs non-diabetic control mice; ††*p*<0.01 vs diabetic wild-type mice

sciatic nerves of *iNos*<sup>-/-</sup> mice. NT immunofluorescence of DRG was increased by 56% in diabetic wild-type mice and by 39% in diabetic *iNos*<sup>-/-</sup> mice compared with the corresponding non-diabetic groups (*p*<0.01 for both comparisons, Fig. 5c,d).

The number of PAR-positive nuclei was 71% higher in the sciatic nerve of diabetic wild-type mice, compared with non-diabetic controls (Fig. 6a,b). The percentage of DRG neurons with weak PAR immunofluorescence was lower, and of those with moderate and intense immunofluorescence higher in diabetic wild-type mice compared with the corresponding control group (Fig. 6c,d). *iNos* gene deficiency reduced the percentage of neurons with moderate and intense PAR fluorescence and increased the percentage of neurons with weak PAR fluorescence in diabetic mice.


## Discussion

Evidence for the important role of iNOS in diabetic complications is emerging. Diabetes-associated iNOS upre-




**Fig. 2** Paw withdrawal latencies in response to radiant heat (a), tail-flick test response latencies (b) and hot-plate test response latencies (c) in control (C) and diabetic (D) wild-type and *iNos*<sup>-/-</sup> mice. Means±

SEM, *n*=8–11 per group. \**p*<0.05 and \*\**p*<0.01 vs corresponding non-diabetic groups; ††*p*<0.01 vs diabetic wild-type mice




**Fig. 4** Intraepidermal nerve fibre profiles in control (C) and diabetic (D) wild-type and *iNos*<sup>-/-</sup> mice. **a** Representative images of intraepidermal nerve fibre profiles, magnification ×200. Arrows indicate intra-epidermal nerve fibres. **b** Skin fibre density of control and diabetic wild-type and *iNos*<sup>-/-</sup> mice. Means±SEM, *n*=8–11 per group. \**p*<0.05 vs control mice

gulation has been found in the retina [21], heart [22], vascular endothelium [23] and smooth muscle layer [24]. Furthermore, high glucose-induced *iNOS* overexpression has been reported for human Schwann cells [14], human retinal and coronary artery endothelial cells [25, 26], and rat and murine glomerular mesangial cells [27, 28]. Advanced glycation end-products induced *iNOS* expression via a p38



**Fig. 5** Representative microphotographs of immunofluorescent staining of NT in sciatic nerves (**a**) and DRG (**c**) of control (C) and diabetic (D) wild-type and *iNos*<sup>-/-</sup> mice. Magnification ×40. NT fluorescence counts in sciatic nerves (**b**) and DRG (**d**) of control and diabetic wild-type and *iNos*<sup>-/-</sup> mice. Means±SEM, *n*=7–11 per group. \*\**p*<0.01 vs non-diabetic control mice; ††*p*<0.01 vs diabetic wild-type mice. RFU, relative fluorescence units



**Fig. 6** Representative microphotographs of immunofluorescent staining of PAR in sciatic nerve (**a**) and DRG neurons (**c**) of control (C) and diabetic (D) wild-type and *iNos*<sup>-/-</sup> mice. Magnification ×40. (**b**) The number of PAR-positive nuclei in sciatic nerve; **d** percentage of DRG neurons with weak, moderate, and intense PAR immunofluorescence. The number of DRG neurons with weak, moderate and intense PAR immunofluorescence was expressed as a percentage of neurons with identifiable PAR immunofluorescence (examples are shown by white arrows) in the dorsal root ganglia of control and diabetic wild-type and *iNos*<sup>-/-</sup> mice. Means±SEM, *n*=8–11 per group. \*\**p*<0.01 vs non-diabetic control mice; ††*p*<0.01 vs diabetic wild-type mice

mitogen-activated protein kinase-dependent pathway [29]. PARP activation, another important player in the regulation of *iNos* gene expression, upregulated iNOS via nuclear factor-kappaB activation [30]. Studies in *iNos*<sup>-/-</sup> mice revealed an important role for iNOS in subnormal retinal oxygenation, leucostasis, blood–renal barrier breakdown and formation of pericyte ghosts and acellular capillaries characteristic of peripheral diabetic retinopathy [31–33]. They have also implicated iNOS in diabetes-induced endothelial dysfunction [23], impaired vascular reactivity [24], cardiomyopathy [34], myocardial ischaemia–reperfusion injury [35] and stroke [36], as well as glomeruloscle-

rosis and tubulointerstitial fibrosis characteristic of chronic diabetic nephropathy [37].

The role of iNOS in diabetic neuropathy has not been studied. *iNos* gene expression has been identified in rat peripheral nerves and dorsal root ganglia [16]. *iNos* mRNA expression was found to be reduced rather than increased in the sciatic nerve of rat models of both short-term and long-term diabetes [16]. The latter is consistent with the demonstration of a diabetes-associated decrease in *iNos* mRNA expression in penile intracavernous nerves [17]. Nevertheless, the present study unequivocally demonstrates a key role of iNOS in peroxynitrite injury to peripheral nerve, motor and sensory nerve conduction deficits, and small-fibre sensory neuropathy.

Our findings are consistent with other reports suggesting that nitrosative stress is a characteristic feature of experimental PDN [38–40]. Accumulation of NT is clearly manifest in peripheral nerve and DRG neurons of wild-type STZ-diabetic mice, consistent with previous observations of our group and others made in STZ-diabetic rodents [4, 6, 7], as well as in *ob/ob* [12] and high-fat-diet fed [13] mice. Using specific markers for certain cell types of PNS, we localised immunoreactive NT in endothelial and Schwann cells of peripheral nerve, as well as neuronal and glial cells of dorsal root ganglia (V. R. Drel and I. G. Obrosova, unpublished results). Thus, nitrosative stress affects all major tissue targets for PDN. Diabetic *iNos*<sup>-/-</sup> mice did not display NT accumulation in peripheral nerve, but were not protected from nitrosative stress in DRG. Despite the latter circumstance, *iNos*<sup>-/-</sup> mice preserved normal MNCV and SNCV. Furthermore, *iNos* gene deficiency alleviated the severity of small-fibre sensory neuropathy. These findings suggest that iNOS-dependent peroxynitrite formation in axons and Schwann cells, rather than cell bodies, of peripheral nerve plays a major role in functional and structural changes of diabetic neuropathy.

Evidence for the important role of PARP activation, another phenomenon closely linked to oxidative–nitrosative stress, in diabetic complications is emerging [18, 41, 42]. We [20, 43–45] and others [15] have demonstrated a key role of PARP activation in motor and sensory nerve conduction and nerve blood flow deficits, thermal hyper- and hypoalgesia, mechanical hyperalgesia, tactile allodynia, exaggerated flinching behaviour in the formalin pain test, and small sensory nerve fibre degeneration associated with PDN, as well as in diabetic autonomic neuropathy. PARP activation manifest by PAR accumulation was present in both sciatic nerve and DRG in diabetic wild-type mice. *iNos* gene deficiency completely prevented diabetes-induced peripheral nerve PAR accumulation, consistent with the lack of enhanced nitrosative stress. Of interest, despite the presence of peroxynitrite injury in DRG of diabetic *iNos*<sup>-/-</sup> mice, PAR accumulation in DRG neurons was markedly alleviat-

ed. The significance and mechanisms of this effect cannot be interpreted based on current knowledge. However, growing evidence suggests that PARP activation is not a mere consequence of oxidative–nitrosative stress, but can be mediated via other biochemical mechanisms, e.g. phosphorylation by extracellular signal regulated kinase [46].

In conclusion, iNOS plays a key role in peroxynitrite injury to peripheral nerve, MNCV and SNCV deficits and small-fibre sensory neuropathy. Nitrosative stress in axons and Schwann cells, rather than DRG neurons, plays a major role in peripheral nerve dysfunction and degeneration associated with PDN. The findings support the rationale for development of specific inhibitors of *iNos* for prevention and treatment of this devastating complication of diabetes mellitus.

**Acknowledgements** The study was supported by the American Diabetes Association Research Grant 7-05-RA-102, the Juvenile Diabetes Research Foundation International Grant 1-2005-223, and the National Institutes of Health Grant DK 071566-01 (all to I. G. Obrosova).

**Duality of interest** The authors declare that there is no duality of interest associated with this manuscript.

## References

1. Boulton AJ, Vinik AI, Arezzo JC et al (2005) American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. *Diabetes Care* 28:956–962
2. Pacher P, Beckman JS, Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease. *Physiol Rev* 87:315–424
3. Szabó C, Ischiropoulos H, Radi R (2007) Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. *Nat Rev Drug Discov* 6:662–680
4. Obrosova IG, Mabley JG, Zsengeller Z et al (2005) Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. *FASEB J* 19:401–403
5. Vareniuk I, Pavlov IA, Drel VR et al (2007) Nitrosative stress and peripheral diabetic neuropathy in leptin-deficient (*ob/ob*) mice. *Exp Neurol* 205:425–436
6. Drel VR, Pacher P, Vareniuk I et al (2007) Evaluation of the peroxynitrite decomposition catalyst Fe(III) tetra-mesitylporphyrin octasulfonate on peripheral neuropathy in a mouse model of type 1 diabetes. *Int J Mol Med* 20:783–792
7. Obrosova IG, Drel VR, Oltman CL et al (2007) Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats. *Am J Physiol Endocrinol Metab* 293:E1645–E1655
8. Hoeldtke RD (2003) Nitrosative stress in early type 1 diabetes. David H. P. Streeten Memorial Lecture. *Clin Auton Res* 13:406–421
9. Ceriello A, Piconi L, Esposito K, Giugliano D (2007) Telmisartan shows an equivalent effect of vitamin C in further improving endothelial dysfunction after glycemia normalization in type 1 diabetes. *Diabetes Care* 30:1694–1698
10. Nourooz-Zadeh J, Ziegler D, Sohr C, Betteridge JD, Knight J, Hothersall J (2006) The use of pholasin as a probe for the determination of plasma total antioxidant capacity. *Clin Biochem* 39:55–61

11. Cheng C, Zochodne DW (2003) Sensory neurons with activated caspase-3 survive long-term experimental diabetes. *Diabetes* 52:2363–2371
12. Drel VR, Mashtalir N, Ilnytska O et al (2006) The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity. *Diabetes* 55:3335–3343
13. Obrosova IG, Ilnytska O, Lyzogubov VV et al (2007) High-fat diet induced neuropathy of pre-diabetes and obesity: effects of ‘healthy’ diet and aldose reductase inhibition. *Diabetes* 56:2598–2608
14. Obrosova IG, Drel VR, Pacher P et al (2005) Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited. *Diabetes* 54:3435–3441
15. Nangle MR, Cotter MA, Cameron NE (2004) Effects of the peroxynitrite decomposition catalyst, FeTMPyP, on function of corpus cavernosum from diabetic mice. *Eur J Pharmacol* 502:143–148
16. Zochodne DW, Verge VM, Cheng C et al (2000) Nitric oxide synthase activity and expression in experimental diabetic neuropathy. *J Neuropathol Exp Neurol* 59:798–807
17. El-Sakka AI, Lin CS, Chui RM, Dahiya R, Lue TF (1999) Effects of diabetes on nitric oxide synthase and growth factor genes and protein expression in an animal model. *Int J Impot Res* 11:123–132
18. Garcia Soriano F, Virag L, Jagtap P et al (2001) Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. *Nat Med* 7:108–113
19. Jagtap P, Szabo C (2005) Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. *Nat Rev Drug Discov* 4:421–440
20. Obrosova IG, Li F, Abatan OI et al (2004) Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. *Diabetes* 53:711–720
21. Ellis EA, Guberski DL, Hutson B, Grant MB (2002) Time course of NADH oxidase, inducible nitric oxide synthase and peroxynitrite in diabetic retinopathy in the BBZ/WOR rat. *Nitric Oxide* 6:295–304
22. Jesmin S, Zaedi S, Maeda S, Yamaguchi I, Goto K, Miyauchi T (2006) Effects of a selective endothelin receptor antagonist on the expressions of iNOS and eNOS in the heart of early streptozotocin-induced diabetic rats. *Exp Biol Med* (Maywood) 231:925–931
23. Nagareddy PR, Xia Z, McNeill JH, MacLeod KM (2005) Increased expression of iNOS is associated with endothelial dysfunction and impaired pressor responsiveness in streptozotocin-induced diabetes. *Am J Physiol Heart Circ Physiol* 289:H2144–H2152
24. Ishikawa T, Kohno F, Kawase R, Yamamoto Y, Nakayama K (2004) Contribution of nitric oxide produced by inducible nitric oxide synthase to vascular responses of mesenteric arterioles in streptozotocin-diabetic rats. *Br J Pharmacol* 141:269–276
25. Steinle JJ (2007) Sympathetic neurotransmission modulates expression of inflammatory markers in the rat retina. *Exp Eye Res* 84:118–125
26. Rajesh M, Mukhopadhyay P, Bátkai S et al (2007) Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. *Am J Physiol Heart Circ Physiol* 293:H610–H619
27. Noh H, Ha H, Yu MR et al (2002) High glucose increases inducible NO production in cultured rat mesangial cells. Possible role in fibronectin production. *Nephron* 90:78–85
28. Sharma K, Danoff TM, DePiero A, Ziyadeh FN (1995) Enhanced expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels: possible mediation via protein kinase C. *Biochem Biophys Res Commun* 207:80–88
29. Chang PC, Chen TH, Chang CJ, Hou CC, Chan P, Lee HM (2004) Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway. *Kidney Int* 65:1664–1675
30. Ha HC, Hester LD, Snyder SH (2002) Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. *Proc Natl Acad Sci USA* 99:3270–3275
31. Berkowitz BA, Luan H, Gupta RR et al (2004) Regulation of the early subnormal retinal oxygenation response in experimental diabetes by inducible nitric oxide synthase. *Diabetes* 53:173–178
32. Leal EC, Manivannan A, Hosoya K et al (2007) Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood–retinal barrier breakdown in diabetic retinopathy. *Invest Ophthalmol Vis Sci* 48:5257–5265
33. Zheng L, Du Y, Miller C et al (2007) Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. *Diabetologia* 50:1987–1996
34. Crespo MJ, Zalacain J, Dunbar DC, Cruz N, Arocho L (2008) Cardiac oxidative stress is elevated at the onset of dilated cardiomyopathy in streptozotocin-diabetic rats. *J Cardiovasc Pharmacol Ther* 13:64–71
35. Marfella R, Di Filippo C, Esposito K et al (2004) Absence of inducible nitric oxide synthase reduces myocardial damage during ischemia reperfusion in streptozotocin-induced hyperglycemic mice. *Diabetes* 53:454–462
36. Kitayama J, Faraci FM, Gunnelt CA, Heistad DD (2006) Impairment of dilator responses of cerebral arterioles during diabetes mellitus: role of inducible NO synthase. *Stroke* 37:2129–2133
37. Trachtman H, Futterweit S, Pine E, Mann J, Valderrama E (2002) Chronic diabetic nephropathy: role of inducible nitric oxide synthase. *Pediatr Nephrol* 17:20–29
38. Coppey LJ, Gellert JS, Davidson EP, Dunlap JA, Lund DD, Yorek MA (2001) Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. *Diabetes* 50:1927–1937
39. Oltman CL, Davidson EP, Coppey LJ et al (2008) Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse. *Diabetes Obes Metab* 10:64–74
40. Ho EC, Lam KS, Chen YS et al (2006) Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. *Diabetes* 55:1946–1953
41. Zheng L, Szabó C, Kern TS (2004) Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. *Diabetes* 53:2960–2967
42. Szabó C, Biser A, Benko R, Böttinger E, Suszták K (2006) Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Lepr<sup>db/db</sup> mice. *Diabetes* 55:3004–3012
43. Li F, Szabó C, Pacher P et al (2004) Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy. *Diabetologia* 47:710–717
44. Ilnytska O, Lyzogubov VV, Stevens MJ et al (2006) Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy. *Diabetes* 55:1686–1694
45. Obrosova IG, Xu W, Lyzogubov VV et al (2008) PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy. *Free Radic Biol Med* 44:972–981
46. Kauppinen TM, Chan WY, Suh SW, Wiggins AK, Huang EJ, Swanson RA (2006) Direct phosphorylation and regulation of poly(ADP-ribose) polymerase-1 by extracellular signal-regulated kinases 1/2. *Proc Natl Acad Sci USA* 103:7136–7141